{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:24:17Z","timestamp":1772051057467,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s00115-006-2112-0","type":"journal-article","created":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T10:15:11Z","timestamp":1153995311000},"page":"45-52","source":"Crossref","is-referenced-by-count":21,"title":["Neuere Antipsychotika","Differences between men and women in side effects of second-generation antipsychotics"],"prefix":"10.1007","volume":"78","author":[{"given":"W.","family":"Aichhorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hinterhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Marksteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2112_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","volume":"19","author":"Aichhorn","year":"2005","unstructured":"Aichhorn W, Weiss U, Marksteiner J et al. (2005) Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 19:395\u2013401","journal-title":"J Psychopharmacol"},{"key":"2112_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","volume":"21","author":"Aichhorn","year":"2006","unstructured":"Aichhorn W, Marksteiner J, Walch T et al. (2006) Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 21:81\u201385","journal-title":"Int Clin Psychopharmacol"},{"key":"2112_CR3","first-page":"137","volume":"56","author":"Aizenberg","year":"1995","unstructured":"Aizenberg D, Zemishlany Z, Dorfman-Etrog P et al. (1995) Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 56:137\u2013141","journal-title":"J Clin Psychiatry"},{"key":"2112_CR4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4088\/JCP.v62n07a07","volume":"62","author":"Aizenberg","year":"2001","unstructured":"Aizenberg D, Modai I, Landa A et al. (2001) Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 62:541\u2013544","journal-title":"J Clin Psychiatry"},{"key":"2112_CR5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686\u20131696","journal-title":"Am J Psychiatry"},{"key":"2112_CR6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0920-9964(02)00305-5","volume":"60","author":"Atmaca","year":"2003","unstructured":"Atmaca M, Kuloglu M, Tezcan E et al. (2003) Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 60:99\u2013100","journal-title":"Schizophr Res"},{"key":"2112_CR7","first-page":"83","volume":"2","author":"Bailey","year":"2002","unstructured":"Bailey MS, Curtis AB (2002) The effects of hormones on arrhythmias in women. Curr Womens Health Rep 2:83\u201388","journal-title":"Curr Womens Health Rep"},{"key":"2112_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","volume":"62","author":"Basson","year":"2001","unstructured":"Basson BR, Kinon BJ, Taylor CC et al. (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231\u2013238","journal-title":"J Clin Psychiatry"},{"key":"2112_CR9","first-page":"529","volume":"37","author":"Beierle","year":"1999","unstructured":"Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529\u2013547","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2112_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-9964(02)00431-0","volume":"62","author":"Bobes","year":"2003","unstructured":"Bobes J, Rejas J, Garcia-Garcia M et al. (2003) Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 62:77\u201388","journal-title":"Schizophr Res"},{"key":"2112_CR11","unstructured":"Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62(Suppl\u00a07):4\u201310"},{"key":"2112_CR12","first-page":"445","volume":"Today","author":"Citrome","year":"2004","unstructured":"Citrome LL (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 40:445\u201364","journal-title":"Drugs"},{"key":"2112_CR13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","volume":"55","author":"Citrome","year":"2004","unstructured":"Citrome L, Jaffe A, Levine J et al. (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55:1006\u20131013","journal-title":"Psychiatr Serv"},{"key":"2112_CR14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","volume":"85","author":"Claus","year":"1992","unstructured":"Claus A, Bollen J, De Cuyper H et al. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85:295\u2013305","journal-title":"Acta Psychiatr Scand"},{"key":"2112_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00421361","volume":"40","author":"Clemens","year":"1974","unstructured":"Clemens JA, Smalstig EB, Sawyer BD (1974) Antipsychotic-Drugs stimulate prolactin-release. Psychopharmacologia 40:123\u2013127","journal-title":"Psychopharmacologia"},{"key":"2112_CR16","first-page":"143","volume":"36","author":"Compton","year":"2002","unstructured":"Compton MT, Miller AH (2002) Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 36:143\u2013164","journal-title":"Psychopharmacol Bull"},{"key":"2112_CR17","unstructured":"Conley RR (2000) Risperidone side effects. J Clin Psychiatry 61(Suppl\u00a08):20\u201323"},{"key":"2112_CR18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S1461145702003012","volume":"5","author":"Croke","year":"2002","unstructured":"Croke S, Buist A, Hackett LP et al. (2002) Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 5:243\u2013247","journal-title":"Int J Neuropsychopharmacol"},{"key":"2112_CR19","first-page":"1204","volume":"28","author":"Datz","year":"1987","unstructured":"Datz FL, Christian PE, Moore J (1987) Gender-related differences in gastric-emptying. J Nucl Med 28:1204\u20131207","journal-title":"J Nucl Med"},{"key":"2112_CR20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","volume":"24","author":"Drici","year":"2001","unstructured":"Drici MD, Clement N (2001) Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575\u2013585","journal-title":"Drug Saf"},{"key":"2112_CR21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","volume":"64","author":"Ebenbichler","year":"2003","unstructured":"Ebenbichler CF, Laimer M, Eder U et al. (2003) Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64:1436\u20131439","journal-title":"J Clin Psychiatry"},{"key":"2112_CR22","first-page":"1026","volume":"43","author":"Flores","year":"2003","unstructured":"Flores PJ, Juarez OH, Flores PC et al. (2003) Effect of menstrual cycle on the pharmacokinetics of ranitidine in healthy volunteers. J Clin Pharmacol 43:1026","journal-title":"J Clin Pharmacol"},{"key":"2112_CR23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0006-3223(97)00488-5","volume":"43","author":"Frankenburg","year":"1998","unstructured":"Frankenburg FR, Zanarini MC, Kando J et al. (1998) Clozapine and body mass change. Biol Psychiatry 43:520\u2013524","journal-title":"Biol Psychiatry"},{"key":"2112_CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","volume":"25","author":"Gex-Fabry","year":"2003","unstructured":"Gex-Fabry M, Balant-Gorgia AE, Balant LP (2003) Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25:46\u201353","journal-title":"Ther Drug Monit"},{"key":"2112_CR25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","volume":"18","author":"Goff","year":"1998","unstructured":"Goff DC, Posever T, Herz L et al. (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296\u2013304","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","volume":"3","author":"Goodnick","year":"2002","unstructured":"Goodnick PJ, Rodriguez L, Santana O (2002) Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3:1381\u20131391","journal-title":"Expert Opin Pharmacother"},{"key":"2112_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-3223(98)00125-5","volume":"45","author":"Grunder","year":"1999","unstructured":"Grunder G, Wetzel H, Schlosser R et al. (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45:89\u201397","journal-title":"Biol Psychiatry"},{"key":"2112_CR28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/0002-9378(90)90557-N","volume":"163","author":"Guengerich","year":"1990","unstructured":"Guengerich FP (1990) Inhibition of oral-contraceptive steroid metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 163:2159\u20132163","journal-title":"Am J Obstet Gynecol"},{"key":"2112_CR29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.7089587","volume":"217","author":"Gur","year":"1982","unstructured":"Gur RC, Gur RE, Obrist WD et al. (1982) Sex and handedness differences in cerebral blood-flow during rest and cognitive activity. Science 217:659\u2013661","journal-title":"Science"},{"key":"2112_CR30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","volume":"62","author":"Haddad","year":"2002","unstructured":"Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649\u20131671","journal-title":"Drugs"},{"key":"2112_CR31","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291\u20132314","journal-title":"Drugs"},{"key":"2112_CR32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1099-1263(199801\/02)18:1<15::AID-JAT463>3.0.CO;2-4","volume":"18","author":"Haddad","year":"1998","unstructured":"Haddad L, Milke P, Zapata L et al. (1998) Effect of the menstrual cycle in ethanol pharmacokinetics. J Appl Toxicol 18:15\u201318","journal-title":"J Appl Toxicol"},{"key":"2112_CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0306-4530(02)00125-7","volume":"28","author":"Hafner","year":"2003","unstructured":"Hafner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 28:17\u201354","journal-title":"Psychoneuroendocrinology"},{"key":"2112_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/oxfordjournals.schbul.a033317","volume":"24","author":"Hafner","year":"1998","unstructured":"Hafner H, an der Heiden W, Behrens S et al. (1998) Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 24:99\u2013113","journal-title":"Schizophr Bull"},{"key":"2112_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","volume":"51","author":"Hagg","year":"2001","unstructured":"Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169\u2013173","journal-title":"Br J Clin Pharmacol"},{"key":"2112_CR36","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/BF00442557","volume":"99","author":"Haring","year":"1989","unstructured":"Haring C, Meise U, Humpel C et al. (1989) Dose-related plasma-levels of clozapine \u2013 influence of smoking-behavior, sex and age. Psychopharmacology 99:S38\u2013S40","journal-title":"Psychopharmacology"},{"key":"2112_CR37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","volume":"24","author":"Harrigan","year":"2004","unstructured":"Harrigan EP, Miceli JJ, Anziano R et al. (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24:62\u201369","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","volume":"26","author":"Hasselstrom","year":"2004","unstructured":"Hasselstrom J, Linnet K (2004) Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 26:486\u2013491","journal-title":"Ther Drug Monit"},{"key":"2112_CR39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-200004000-00036","volume":"20","author":"Hill","year":"2000","unstructured":"Hill RC, McIvor RJ, Wojnar-Horton RE et al. (2000) Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol 20:285\u2013286","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","volume":"55","author":"Homel","year":"2002","unstructured":"Homel P, Casey D, Allison DB (2002) Changes in body mass index for individuals with and without schizophrenia, 1987\u20131996. Schizophr Res 55:277\u2013284","journal-title":"Schizophr Res"},{"key":"2112_CR41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","volume":"20","author":"Hummer","year":"2004","unstructured":"Hummer M, Huber J (2004) Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20:189\u2013197","journal-title":"Curr Med Res Opin"},{"key":"2112_CR42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1176\/appi.ajp.162.1.162","volume":"162","author":"Hummer","year":"2005","unstructured":"Hummer M, Malik P, Gasser RW et al. (2005) Osteoporosis in patients with schizophrenia. Am J Psychiatry 162:162\u2013167","journal-title":"Am J Psychiatry"},{"key":"2112_CR43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002280050654","volume":"55","author":"Kamimori","year":"1999","unstructured":"Kamimori GH, Joubert A, Otterstetter R et al. (1999) The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. Eur J Clin Pharmacol 55:445\u2013449","journal-title":"Eur J Clin Pharmacol"},{"key":"2112_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-199834030-00003","volume":"34","author":"Kashuba","year":"1998","unstructured":"Kashuba ADM, Nafziger AN (1998) Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 34:203\u2013218","journal-title":"Clin Pharmacokinet"},{"key":"2112_CR45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-2000-7974","volume":"33","author":"Kirchheiner","year":"2000","unstructured":"Kirchheiner J, Berghofer A, Bolk-Weischedel D (2000) Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 33:78\u201380","journal-title":"Pharmacopsychiatry"},{"key":"2112_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, de Coster R et al. (1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57\u201361","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","volume":"24","author":"Knegtering","year":"2004","unstructured":"Knegtering R, Castelein S, Bous H et al. (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24:56\u201361","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR48","first-page":"419","volume":"25","author":"Kopecek","year":"2004","unstructured":"Kopecek M, Bares M, Svarc J et al. (2004) Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 25:419\u2013422","journal-title":"Neuro Endocrinol Lett"},{"key":"2112_CR49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.156.2.312","volume":"156","author":"Kraus","year":"1999","unstructured":"Kraus T, Haack M, Schuld A et al. (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312\u2013314","journal-title":"Am J Psychiatry"},{"key":"2112_CR50","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4088\/JCP.v65n0517","volume":"65","author":"Lamberti","year":"2004","unstructured":"Lamberti JS, Crilly JF, Maharaj K et al. (2004) Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65:702\u2013706","journal-title":"J Clin Psychiatry"},{"key":"2112_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s001150050232","volume":"69","author":"Lanczik","year":"1998","unstructured":"Lanczik M, Knoche M, Fritze J (1998) [Psychopharmacotherapy during pregnancy and lactation. 1: Pregnancy]. Nervenarzt 69:1\u20139","journal-title":"Nervenarzt"},{"key":"2112_CR52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s001150050233","volume":"69","author":"Lanczik","year":"1998","unstructured":"Lanczik M, Knoche M, Fritze J (1998) [Psychopharmacotherapy in pregnancy and lactation. 2: Lactation]. Nervenarzt 69:10\u201314","journal-title":"Nervenarzt"},{"key":"2112_CR53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","volume":"60","author":"Lane","year":"1999","unstructured":"Lane HY, Chang YC, Chang WH et al. (1999) Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 60:36\u201340","journal-title":"J Clin Psychiatry"},{"key":"2112_CR54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/266639a0","volume":"266","author":"Langer","year":"1977","unstructured":"Langer G, Sachar EJ, Gruen PH et al. (1977) Human prolactin responses to neuroleptic drugs correlate with anti-schizophrenic potency. Nature 266:639\u2013640","journal-title":"Nature"},{"key":"2112_CR55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E et al. (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123\u2013136","journal-title":"Schizophr Res"},{"key":"2112_CR56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","volume":"66","author":"McKenna","year":"2005","unstructured":"McKenna K, Koren G, Tetelbaum M et al. (2005) Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66:444\u2013449","journal-title":"J Clin Psychiatry"},{"key":"2112_CR57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"Meibohm","year":"2002","unstructured":"Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329\u2013342","journal-title":"Clin Pharmacokinet"},{"key":"2112_CR58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"Melkersson","year":"2005","unstructured":"Melkersson K (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66:761\u2013767","journal-title":"J Clin Psychiatry"},{"key":"2112_CR59","doi-asserted-by":"crossref","unstructured":"Melkersson KI, Dahl ML (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 170:157\u2013166","DOI":"10.1007\/s00213-003-1529-4"},{"key":"2112_CR60","doi-asserted-by":"crossref","unstructured":"Melkersson KI, Dahl ML, Hulting AL (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 175:1\u20136","DOI":"10.1007\/s00213-004-1922-7"},{"key":"2112_CR61","first-page":"25","volume":"63","author":"Meltzer","year":"2002","unstructured":"Meltzer HY, Davidson M, Glassman AH et al. (2002) Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 63:25\u201329","journal-title":"J Clin Psychiatry"},{"key":"2112_CR62","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"Montgomery","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M et al. (2004) Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65:1491\u20131498","journal-title":"J Clin Psychiatry"},{"key":"2112_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects \u2013 A comprehensive literature review. CNS Drugs 19:1\u201393","journal-title":"CNS Drugs"},{"key":"2112_CR64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"O","year":"2005","unstructured":"O\u2019Keane V, Meaney AM (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26\u201331","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(02)00430-9","volume":"62","author":"Oksbjerg","year":"2003","unstructured":"Oksbjerg DS, Munk LT, Mellemkjaer L et al. (2003) Schizophrenia and the risk for breast cancer. Schizophr Res 62:89\u201392","journal-title":"Schizophr Res"},{"key":"2112_CR66","first-page":"5","volume":"6","author":"Ollendorf","year":"2004","unstructured":"Ollendorf DA, Joyce AT, Rucker M (2004) Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 6:5","journal-title":"Med Gen Med"},{"key":"2112_CR67","first-page":"403","volume":"14","author":"Ostbye","year":"2004","unstructured":"Ostbye T, Curtis LH, Masselink LE et al. (2004) Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf 14:403\u2013405","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2112_CR68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","volume":"199","author":"Parkinson","year":"2004","unstructured":"Parkinson A, Mudra DR, Johnson C et al. (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193\u2013209","journal-title":"Toxicol Appl Pharmacol"},{"key":"2112_CR69","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"Petty","year":"1999","unstructured":"Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35:S67\u2013S73","journal-title":"Schizophr Res"},{"key":"2112_CR70","first-page":"235","volume":"33","author":"Pollock","year":"1997","unstructured":"Pollock BG (1997) Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 33:235\u2013241","journal-title":"Psychopharmacol Bull"},{"key":"2112_CR71","first-page":"99","volume":"28","author":"Prior","year":"2003","unstructured":"Prior TI, Baker GB (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28:99\u2013112","journal-title":"J Psychiatry Neurosci"},{"key":"2112_CR72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0028-3932(99)00086-X","volume":"38","author":"Ragland","year":"2000","unstructured":"Ragland JD, Coleman AR, Gur RC et al. (2000) Sex differences in brain-behavior relationships between verbal episodic memory and resting regional cerebral blood flow. Neuropsychologia 38:451\u2013461","journal-title":"Neuropsychologia"},{"key":"2112_CR73","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.285.10.1322","volume":"285","author":"Rodriguez","year":"2001","unstructured":"Rodriguez I, Kilborn MJ, Liu XK et al. (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285:1322\u20131326","journal-title":"JAMA"},{"key":"2112_CR74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004714-200304000-00013","volume":"23","author":"Roe","year":"2003","unstructured":"Roe CM, Odell KW, Henderson RR (2003) Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol 23:197\u2013200","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00023210-200115070-00004","volume":"15","author":"Russell","year":"2001","unstructured":"Russell JM, Mackell JA (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15:537\u2013551","journal-title":"CNS Drugs"},{"key":"2112_CR76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(02)00530-3","volume":"66","author":"Salokangas","year":"2004","unstructured":"Salokangas RKR (2004) Gender and the use of neuroleptics in schizophrenia. Schizophr Res 66:41\u201349","journal-title":"Schizophr Res"},{"key":"2112_CR77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063574","volume":"46","author":"Schlosser","year":"2002","unstructured":"Schlosser R, Grunder G, Anghelescu I et al. (2002) Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46:33\u201340","journal-title":"Neuropsychobiology"},{"key":"2112_CR78","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","volume":"161","author":"Seeman","year":"2004","unstructured":"Seeman MV (2004) Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 161:1324\u20131333","journal-title":"Am J Psychiatry"},{"key":"2112_CR79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002280050615","volume":"55","author":"Tamminga","year":"1999","unstructured":"Tamminga WJ, Wemer J, Oosterhuis B et al. (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55:177\u2013184","journal-title":"Eur J Clin Pharmacol"},{"key":"2112_CR80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1020464017021","volume":"73","author":"Tandon","year":"2002","unstructured":"Tandon R (2002) Safety and tolerability: how do newer generation \u201catypical\u201d antipsychotics compare? Psychiatr Q 73:297\u2013311","journal-title":"Psychiatr Q"},{"key":"2112_CR81","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","volume":"192","author":"Tracy","year":"2005","unstructured":"Tracy TS, Venkataramanan R, Glover DD et al. (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192:633\u2013639","journal-title":"Am J Obstet Gynecol"},{"key":"2112_CR82","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4088\/JCP.v63n0508","volume":"63","author":"Umbricht","year":"2002","unstructured":"Umbricht DS, Wirshing WC, Wirshing DA et al. (2002) Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 63:420\u2013424","journal-title":"J Clin Psychiatry"},{"key":"2112_CR83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","volume":"65","author":"Volavka","year":"2004","unstructured":"Volavka J, Czobor P, Cooper TB et al. (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57\u201361","journal-title":"J Clin Psychiatry"},{"key":"2112_CR84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","volume":"59","author":"Wang","year":"2002","unstructured":"Wang PS, Walker AM, Tsuang MT et al. (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59:1147\u20131154","journal-title":"Arch Gen Psychiatry"},{"key":"2112_CR85","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","volume":"25","author":"Weiss","year":"2005","unstructured":"Weiss U, Marksteiner J, Kemmler G et al. (2005) Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 25:570\u2013574","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR86","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004714-199908000-00006","volume":"19","author":"Wetterling","year":"1999","unstructured":"Wetterling T, Mussigbrodt HE (1999) Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 19:316\u2013321","journal-title":"J Clin Psychopharmacol"},{"key":"2112_CR87","doi-asserted-by":"crossref","unstructured":"Wilner KD, Demattos SB, Anziano RJ et al. (2000) Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 49(Suppl\u00a01):43S\u201347S","DOI":"10.1046\/j.1365-2125.2000.00152.x"},{"key":"2112_CR88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-9964(01)00271-7","volume":"56","author":"Wirshing","year":"2002","unstructured":"Wirshing DA, Pierre JM, Marder SR et al. (2002) Sexual side effects of novel antipsychotic medications. Schizophr Res 56:25\u201330","journal-title":"Schizophr Res"},{"key":"2112_CR89","first-page":"105","volume":"2","author":"Wolbrette","year":"2002","unstructured":"Wolbrette D (2002) Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep 2:105\u2013109","journal-title":"Curr Womens Health Rep"},{"key":"2112_CR90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1552-4604.1997.tb04330.x","volume":"37","author":"Wright","year":"1997","unstructured":"Wright CE, Sisson TL, Ichhpurani AK et al. (1997) Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 37:520\u2013525","journal-title":"J Clin Pharmacol"},{"key":"2112_CR91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-2952(95)00120-O","volume":"50","author":"Zhang","year":"1995","unstructured":"Zhang ZY, Kaminsky LS (1995) Characterization of Human Cytochromes P450 Involved in Theophylline 8-Hydroxylation. Biochem Pharmacol 50:205\u2013211","journal-title":"Biochem Pharmacol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-006-2112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-006-2112-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-006-2112-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:04:18Z","timestamp":1683529458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-006-2112-0"}},"subtitle":["Unterschiede im Nebenwirkungsprofil bei Frauen und M\u00e4nnern"],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["2112"],"URL":"https:\/\/doi.org\/10.1007\/s00115-006-2112-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}